Bevacizumab Biosimilar - Anti-VEGF mAb - Research Grade
Source
DrugBank DB00112
Species
Human
Expression system
Mammalian cells
Molecular weight
149kDa
Purity
>85%
Buffer
PBS pH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
Bevacizumab,Bevacizumab,VEGF,anti-VEGF
Reference
PX-TA1006
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG1
Clonality
Monoclonal Antibody
Description of Bevacizumab Biosimilar - Anti-VEGF mAb - Research Grade
General information about Bevacizumab
Bevacizumab, is classified as a monoclonal antibody and/or anti-angiogenesis drug. It is a comparatively new type of cancer therapy. Antibodies are an essential part of the immune system. The body creates antibodies in response to an antigen entering the body. These antibodies attach themselves to the antigen, to mark it for destruction by the body’s immune system. Bevacizumab allows human body to target specific cells, causing less toxicity to healthy cells. It works by interfering with the process of angiogenesis by targeting and inhibiting human vascular endothelial growth factor (VEGF). VEGF is a cytokine (a small protein released by cells that have specific effects on the behavior of cells) which when it interacts with its receptors in the cell leads to new blood vessel formation or angiogenesis. This product is for research use only.
Reviews
There are no reviews yet.